Simplify Asset Management Inc. Buys Shares of 37,742 Pacira BioSciences, Inc. (NASDAQ:PCRX)

Simplify Asset Management Inc. bought a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 37,742 shares of the company's stock, valued at approximately $711,000. Simplify Asset Management Inc. owned about 0.08% of Pacira BioSciences at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Caitlin John LLC raised its stake in shares of Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after buying an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC raised its position in Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $62,000 after acquiring an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after acquiring an additional 513 shares during the period. Virtus Investment Advisers Inc. purchased a new stake in Pacira BioSciences in the 3rd quarter worth approximately $98,000. Finally, Quest Partners LLC boosted its position in Pacira BioSciences by 137.6% in the 3rd quarter. Quest Partners LLC now owns 9,410 shares of the company's stock worth $142,000 after purchasing an additional 5,449 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Pacira BioSciences Trading Up 3.6 %

Shares of Pacira BioSciences stock traded up $0.88 during mid-day trading on Thursday, hitting $25.30. The stock had a trading volume of 803,782 shares, compared to its average volume of 916,923. The firm has a market cap of $1.17 billion, a P/E ratio of -12.46 and a beta of 0.86. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The firm has a 50-day moving average of $24.71 and a two-hundred day moving average of $19.83. Pacira BioSciences, Inc. has a 12-month low of $11.16 and a 12-month high of $31.67.

Analysts Set New Price Targets

Several research firms have recently issued reports on PCRX. Needham & Company LLC increased their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Barclays increased their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Royal Bank of Canada reissued a "sector perform" rating and set a $18.00 target price on shares of Pacira BioSciences in a research note on Tuesday, January 14th. HC Wainwright raised their price target on shares of Pacira BioSciences from $57.00 to $70.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Finally, Truist Financial raised Pacira BioSciences from a "sell" rating to a "hold" rating and increased their target price for the company from $8.00 to $25.00 in a report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Pacira BioSciences has a consensus rating of "Hold" and an average target price of $27.22.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.